Same-visit hormone results. Simpler IVF workflows. More time for care.
Current platform status: Research Use Only (RUO).
Simpler start.
For on-site testing.
Preparation and analysis, integrated.
The value is practical: less work around every sample, results closer to the patient, and a platform model built around repeat use.
Approximately one minute of hands-on time. Automated preparation and measurement mean fewer separate tasks between the sample and the result.
Designed for hormone results during the same visit, so patients and their care team can discuss the result together while the questions are still in the room.
A benchtop analyzer paired with single-use cartridges connects instrument placement with repeat testing. A focused IVF application gives the model a clear starting point.
Plasmatrix reports that two pilot studies confirmed central-laboratory equivalence under the conditions evaluated.
Explore the technologyAdvanced technology.
Intentionally straightforward.
Whole-blood separation. Precision metering. Controlled mixing and incubation. Our immunochemistry and sensitive optical analysis—all coordinated within one platform.
A benchtop analyzer and single-use cartridge bring preparation and measurement into one automated run. The science is integrated inside the system, so your team has fewer separate steps to manage.
See how it comes togetherWhole-blood separation and precision metering are integrated into the cartridge workflow.
Mixing and incubation run in a coordinated sequence, consolidating separate preparation tasks.
Our immunochemistry and sensitive optical detection produce digital quantitative hormone results.
Digital interfaces are plug and play by design for easy integration into EHR and LIS systems.
Bring the testing workflow closer to the clinic. Plasmatrix consolidates preparation, reaction, and measurement into one system, reducing the separate instruments and manual transfers in the process.
20 minutes from sample to results.Approximately one minute of hands-on time. Automated preparation, reaction, and optical readout in one integrated run.
Load the sample and single-use cartridge following the applicable research protocol. Touchscreen guidance starts the integrated run, with approximately one minute of hands-on time.
When testing happens elsewhere, the result can arrive after the conversation ends. Plasmatrix is designed to make hormone results part of the same visit, without manual preparation or handoffs once the sample is loaded.
Explore a clinic evaluationDigital quantitative hormone results are designed to be ready within the same visit, keeping information closer to the clinical conversation.
Automated separation, metering, mixing, incubation, and optical readout consolidate separate tasks into one run. Approximately one minute of hands-on time gets the process started.
A compact benchtop footprint, guided operation, and EHR/LIS integration by design bring the workflow together around your team.
Plasmatrix combines automated microfluidics, our immunochemistry, and high-sensitivity optical detection. Sample preparation, reaction control, and quantitative measurement work together as a single integrated process.
Plasmatrix reports that two pilot studies confirmed central-laboratory equivalence under the conditions evaluated.
Whole-blood separation, precise fluid metering, mixing, and incubation are coordinated within the cartridge workflow.
Assay chemistry and instrument-based detection work together to support digital quantitative hormone measurement.
Sensitive optical detection measures assay signals to produce digital quantitative readouts, within the same platform that prepares the sample.
An independent published HBsAg lateral flow study demonstrated laboratory-method correlation, strip stability, and repeat optical readout performance under the conditions tested.
Signal-to-cutoff ratios were compared using HBsAg Performance Panel samples.
Seven time points; serum samples at 0, 0.5, and 5 ng/mL HBsAg. The authors reported no significant performance change under the study conditions.
Fifteen readings of the same assayed strips assessed reader repeatability across three concentrations.
Coefficient of variation within the repeated optical readings.Founder & CEO
Zulma Guillot leads Plasmatrix Biotech with a perspective rooted in clinical operations leadership, health equity, and patient-focused strategy. Her focus is translating the complexity of testing into technology that is practical for teams and meaningful for the people they serve.
She guides platform development, commercialization strategy, and partnerships around a clear goal: making advanced testing easier to access and simpler to use. Advocacy and mentorship, gender equality in STEM, and addressing disparities in diagnostics inform that work.
Contact Plasmatrix for inquiriesCurrent status: Research Use Only.
Plasmatrix is currently available for Research Use Only (RUO). Clinical diagnostic use requires assay-specific validation and applicable regulatory authorization.
Approximately one minute of hands-on time and 20 minutes from sample to results, as tested by Plasmatrix. Plasmatrix reports that two pilot studies confirmed central-laboratory equivalence under the conditions evaluated.
The benchtop format combines sample preparation and analysis, with guided operation designed to simplify onboarding. Digital interfaces are plug and play by design for easy integration into EHR and LIS systems.
We welcome research and assay evaluation collaborators, reproductive-health innovators, engineering and manufacturing partners, commercialization partners, and bankers and investors interested in the next stage of platform development.
Bring your clinical perspective, technical expertise, or capital strategy. Together, we can advance simpler hormone testing—from platform evaluation to commercial readiness.
We support the United Nations Sustainable Development Goals and ECOSOC’s work toward inclusive, sustainable development.
Our commitments connect reproductive-health innovation with healthcare access, advocacy, mentorship, and collaboration.
Developing practical diagnostic innovation around the people and communities it is designed to serve.
Championing women-led innovation, advocacy, mentorship, and opportunity in STEM.
Working toward more equitable healthcare access and addressing disparities in diagnostics.
Bringing science, industry, and communities together around shared health priorities.
Woman-led innovation. Shared responsibility.
Clinical perspective and patient-focused strategy guide the way forward.